Establishment Labs Announces Participation in Two Upcoming Investment Conferences

Rhea-AI Summary

Establishment Labs (NASDAQ: ESTA), a leader in medical technology focused on women's health, announced its participation in two key investment conferences. CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Jefferies Global Healthcare Conference on June 5, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Live webcasts of their presentations will be accessible via the company's investor relations website. Establishment Labs is renowned for its Femtech solutions, including the Motiva® breast implants and Motiva Flora® tissue expanders, with a presence in over 85 countries. The company's innovations are backed by extensive patent applications and scientific research, and its manufacturing facilities in Costa Rica comply with stringent regulatory standards.

Positive

• Participation in prestigious investment conferences could attract new investors.
• Live webcasts provide transparency and accessibility to stakeholders.
• Establishment Labs has a strong global presence in over 85 countries.
• The Motiva® devices and Motiva Flora® tissue expanders set new standards in safety and patient satisfaction.
• Backed by over 200 patent applications and supported by more than 50 scientific studies.
• Compliant manufacturing facilities in Costa Rica enhance credibility.

Negative

• No mention of new product launches or financial performance updates.
• Possible investor fatigue with frequent conference participation without substantial news.
• Regulatory approval for Motiva Implants® in the United States is still pending.

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 Jefferies Global Healthcare Conference being held June 5-6, 2024. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak to conference attendees on Wednesday, June 5, 2024 at 8:30 a.m. ET.

Mr. Chacón-Quirós and Mr. Denhoy will also participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held June 10-13, 2024, and are scheduled to speak to conference attendees on Monday, June 10, 2024 at 8:00 a.m. ET.

Live webcasts of the presentations will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523056889/en/

Investor/Media Contact:

Raj Denhoy

415 828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

What is the stock symbol for Establishment Labs?

The stock symbol for Establishment Labs is ESTA.

When will Establishment Labs present at the Jefferies Global Healthcare Conference?

Establishment Labs will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 8:30 a.m. ET.

When is the Goldman Sachs 45th Annual Global Healthcare Conference?

The Goldman Sachs 45th Annual Global Healthcare Conference will be held from June 10-13, 2024.

How many countries are Motiva devices available in?

Motiva devices are available in over 85 countries.

Where can I watch the live webcasts of Establishment Labs' presentations?

Live webcasts will be available on the company's investor relations website.

What are Motiva Flora® tissue expanders used for?

Motiva Flora® tissue expanders are used to improve outcomes in breast reconstruction following breast cancer.

How many patent applications has Establishment Labs filed?

Establishment Labs has filed over 200 patent applications.

Which regulatory standards do Establishment Labs' manufacturing facilities comply with?

Establishment Labs' facilities comply with ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program.